Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease (PSYCHO-PERF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03793491|
Recruitment Status : Active, not recruiting
First Posted : January 4, 2019
Last Update Posted : January 4, 2019
|Condition or disease||Intervention/treatment|
|Parkinson Disease||Other: TCI scale Other: PDQ-39 scale|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Study About Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs (by Subcutaneous Apomorphine Infusion or Intrajejunal Infusion of Levodopa-carbidopa), in Parkinson's Disease|
|Actual Study Start Date :||December 18, 2018|
|Estimated Primary Completion Date :||December 18, 2020|
|Estimated Study Completion Date :||June 18, 2021|
Patients having Parkinson's disease
Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
Other: TCI scale
TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
Other: PDQ-39 scale
PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
Other Name: Parkinson's Disease Questionnaire (PDQ-39)
- percent of improvement of quality of life score at 6 months after the beginning of the second line treatment [ Time Frame: day 1 ]Evaluation of life quality using Parkinson's Disease Questionnaire (PDQ-39) scale before (day 1) and after (6 month) the starting of perfusion treatment
- percent of improvement of quality of life score at 6 months after the beginning of the second line treatment [ Time Frame: 6 months ]Evaluation of life quality using PDQ-39 scale before and after the starting of perfusion treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03793491
|Toulouse, France, 31000|
|Principal Investigator:||Chrisitine BREFEL COURBON, PH||University Hospital, Toulouse|